# SUBSTANTIAL EQUIVALENCE DETERMINATIONDECISION SUMMARYASSAY ONLY TEMPLATE

A. 510(k) Number: k113389   
B. Purpose for Submission: New device   
C. Measurand: Urea Nitrogen (BUN) Creatinine Uric acid Creatinine Kinase

# D. Type of Test:

# E. Applicant:

# F. Proprietary and Established Names:

ACE BUN/ Urea Reagent ACE Creatinine Reagent ACE Uric Acid Reagent ACE CK Reagent

# G. Regulatory Information:

<table><tr><td colspan="1" rowspan="1">Analyte</td><td colspan="1" rowspan="1">Regulation</td><td colspan="1" rowspan="1">ProductCode</td><td colspan="1" rowspan="1">Classification</td><td colspan="1" rowspan="1">Panel</td></tr><tr><td colspan="1" rowspan="1">BUN</td><td colspan="1" rowspan="1">21 CFR 862.1770Urea nitrogen test system</td><td colspan="1" rowspan="1">CDN</td><td colspan="1" rowspan="1">I</td><td colspan="1" rowspan="1">Clinical Chemistry(75)</td></tr><tr><td colspan="1" rowspan="1">Creatinine</td><td colspan="1" rowspan="1">21 CFR 862.1225Creatinine test system</td><td colspan="1" rowspan="1">CGX</td><td colspan="1" rowspan="1">Ⅱ</td><td colspan="1" rowspan="1">Clinical Chemistry(75)</td></tr><tr><td colspan="1" rowspan="1">Uric Acid</td><td colspan="1" rowspan="1">21 CFR 862.1775Uric acid test system</td><td colspan="1" rowspan="1">KNK</td><td colspan="1" rowspan="1">I. reserved</td><td colspan="1" rowspan="1">Clinical Chemistry(75)</td></tr><tr><td colspan="1" rowspan="1">CK</td><td colspan="1" rowspan="1">21 CFR 862.1215Creatine phosphokinase /creatine kinase or isoenzymes</td><td colspan="1" rowspan="1">CGS</td><td colspan="1" rowspan="1">I</td><td colspan="1" rowspan="1">Clinical Chemistry(75)</td></tr></table>

# H. Intended Use:

1. Intended use(s): See indication for use below

2. Indication(s) for use:

The ACE BUN/Urea Reagent is intended for the quantitative determination of blood urea nitrogen (BUN) concentration in serum using the ACE Axcel Clinical Chemistry System. BUN measurements are used in the diagnosis and treatment of certain renal and metabolic diseases. This test is intended for use in clinical laboratories or physician office laboratories. For in vitro diagnostic use only.

The ACE Creatinine Reagent is intended for the quantitative determination of creatinine concentration in serum using the ACE Axcel Clinical Chemistry System. Creatinine measurements are used in the diagnosis and treatment of renal diseases, in monitoring renal dialysis, and as a calculation basis for measuring other urine analytes. This test is intended for use in clinical laboratories or physician office laboratories. For in vitro diagnostic use only.

The ACE Uric Acid Reagent is intended for the quantitative determination of uric acid concentration in serum using the ACE Axcel Clinical Chemistry System. Uric acid measurements are used in the diagnosis and treatment of numerous renal and metabolic disorders, including renal failure, gout, leukemia, psoriasis, starvation or other wasting conditions and of patients receiving cytotoxic drugs. This test is intended for use in clinical laboratories or physician office laboratories. For in vitro diagnostic use only.

The ACE CK Reagent is intended for the quantitative determination of creatine kinase activity in serum using the ACE Axcel Clinical Chemistry System. Measurement of creatine kinase is used in the diagnosis and treatment of myocardial infarction and muscle diseases such as progressive, Duchenne-type muscular dystrophy. This test is intended for use in clinical laboratories or physician office laboratories. For in vitro diagnostic use only.

3. Special conditions for use statement(s): For in vitro diagnostic use only For prescription use and Point-of-Care settings

4. Special instrument requirements:

# ACE Axcel Clinical Chemistry System

# I. Device Description:

The ACE BUN/Urea Reagent consists of a single reagent bottle containing $\alpha \cdot$ -Ketoglutarate $( 4 . 0 \mathrm { m m o l / L } )$ , Urease (Jack Bean) ${ > } 1 5 { , } 0 0 0 \mathrm { U / L }$ , Glutamate dehydrogenase (GLDH) (Beef Liver) ${ > } 1 6 6 7 \mathrm { U } / \mathrm { L }$ , Adenosine diphosphate (ADP) $2 . 0 \mathrm { m m o l / L }$ , Nicotinamide adenine dinucleotide, reduced (NADH) $0 . 2 8 \mathrm { m m o l / L }$ , buffer, preservative and stabilizer.

The ACE Creatinine Reagent consists of two reagent bottles, the Sodium Hydroxide Reagent and Picric Acid Reagent. The Sodium Hydroxide Reagent (R1) contains Sodium Hydroxide $0 . 2 5 \mathrm { m o l / L }$ and surfactants. The Picric Acid Reagent (R2) contains Picric Acid $2 0 . 5 \mathrm { m m o l / L } .$

The ACE Uric Acid Reagent consists of a single reagent bottle containing 4-Aminoantipyrine (AAP) $0 . 5 \mathrm { m m o l / L }$ , Dichlorohydroxybenzene sulfonic acid (DHBS) $1 . 8 \mathrm { m m o l / L }$ , Peroxidase (Horseradish) $> 3 5 0 0 \mathrm { U / L }$ , Uricase (Bacillus) $> 2 0 0 \mathrm { U / L }$ and stabilizers and preservatives.

The ACE CK Reagent consists of two reagent bottles, Buffer and Substrate. The Buffer Reagent (R1) contains Imidazole Buffer $\mathrm { \ p H } 6 . 5$ at $2 5 ^ { \circ } \mathrm { C }$ ), Glucose 27 mmol/L, Nacetylcysteine $2 7 \mathrm { m m o l } / \mathrm { L }$ , Magnesium acetate $1 4 \mathrm { m m o l / L }$ , EDTA $2 \mathrm { m m o l / L }$ , NADP 2.7 mmol/L, Hexokinase (recombinant yeast, modified) ${ > } 5 \mathrm { \ K U / L }$ . The Substrate Reagent (R2) contains Creatine phosphate $1 6 0 \mathrm { m m o l / L }$ , EDTA $2 \mathrm { m m o l / L }$ , ADP $1 1 \ \mathrm { m m o l / L }$ , AMP 28 mmol/L, Diadenosine pentaphosphate $5 5 \ \mathrm { \mu m o l / L }$ and Glucose-6-phosphate dehydrogenase (E coli) ${ > } 1 4$ KU/L.

# J. Substantial Equivalence Information:

1. Predicate device name(s): ACE BUN/Urea Reagent ACE Creatinine Reagent ACE Uric Acid Reagent ACE CK Reagent

2. Predicate 510(k) number(s): k930104

3. Comparison with predicate:

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>ACE BUN/Urea Reagent(Candidate device)</td><td rowspan=1 colspan=1>ACE BUN/Urea Reagent(Predicate device,k930104)</td></tr><tr><td rowspan=1 colspan=1>IntendedUse/Indicationsfor use</td><td rowspan=1 colspan=1>The ACE BUN Reagent is intendedfor the quantitative determination ofblood urea nitrogen concentration inserum. BUN measurements are used inthe diagnosis and treatment of certainrenal and metabolic diseases.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Instrument/Platform</td><td rowspan=1 colspan=1>ACE Axcel Clinical Chemistry System</td><td rowspan=1 colspan=1>ACE Clinical ChemistrySystems</td></tr><tr><td rowspan=1 colspan=1>CalibrationStability</td><td rowspan=1 colspan=1>7 days</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>On- BoardStability</td><td rowspan=1 colspan=1>30 days</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Basic Principle</td><td rowspan=1 colspan=1>Enzymatic method for urea nitrogen</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Sample Stability</td><td rowspan=1 colspan=1>2-5 days at 2-8°Cup to several weeks at -20°C; and at -70°C or lower for longer periods</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>UnopenedStability</td><td rowspan=1 colspan=1>until the expiration date shown on thebox and bottle labels when stored in therefrigerator at 2-8°</td><td rowspan=1 colspan=1>Same</td></tr></table>

<table><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">ACE Creatinine Reagent(Candidate device)</td><td colspan="1" rowspan="1">Ace Creatinine Reagent(Predicate, k930104)</td></tr><tr><td colspan="1" rowspan="1">IntendedUse/Indicationsfor use</td><td colspan="1" rowspan="1">The ACE Creatinine Reagent isintended for the quantitativedetermination of creatinineconcentration in serum. Creatininemeasurements are used in the diagnosisand treatment of renal diseases, inmonitoring renal dialysis, and as acalculation basis for measuring otherurine analytes.</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Instrument/Platform</td><td colspan="1" rowspan="1">ACE Axcel Clinical ChemistrySystem</td><td colspan="1" rowspan="1">ACE' Clinical ChemistrySystem</td></tr><tr><td colspan="1" rowspan="1">CalibrationStability</td><td colspan="1" rowspan="1">2 days</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">On- BoardStability</td><td colspan="1" rowspan="1">10 days</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Basic Principle</td><td colspan="1" rowspan="1">Alkaline picrate chemistry.</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Sample Stability</td><td colspan="1" rowspan="1">7 days at 2-8°;3 month at -20°</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">UnopenedStability</td><td colspan="1" rowspan="1">until the expiration date shown on thebox and bottle labels when stored in therefrigerator at 2-8°C</td><td colspan="1" rowspan="1">Same</td></tr></table>

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>ACE Uric Acid Reagent(Candidate device)</td><td rowspan=1 colspan=1>ACE Uric Acid Reagent(Predicate, k930104)</td></tr><tr><td rowspan=1 colspan=1>IntendedUse/Indicationsfor use</td><td rowspan=1 colspan=1>The ACE Uric Acid Reagent isintended for the quantitativedetermination of uric acidconcentration in serum. Uric acidmeasurements are used in thediagnosis and treatment ofnumerous renal and metabolicdisorders, including renal failure,gout, psoriasis, starvation or otherwasting conditions and of patientsreceiving cytotoxic drugs.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Instrument/Platform</td><td rowspan=1 colspan=1>ACE Axcel Clinical ChemistrySystem,</td><td rowspan=1 colspan=1>ACE Clinical ChemistrySystem</td></tr><tr><td rowspan=1 colspan=1>Calibration &amp;On- BoardStability</td><td rowspan=1 colspan=1>30 days</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Basic Principle</td><td rowspan=1 colspan=1>Coupled Enzymatic method</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Sample Stability</td><td rowspan=1 colspan=1>3-5 days at 2-8°C6 months below -20°C.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>UnopenedStability</td><td rowspan=1 colspan=1>Until the expiration date shown onthe box and bottle labels whenstored in the refrigerator at 2-8°</td><td rowspan=1 colspan=1>Same</td></tr></table>

<table><tr><td></td><td>ACE CK Reagent (Candidate device)</td><td>ACE CK Reagent (Predicate, k930104)</td></tr><tr><td colspan="1" rowspan="1">Intended Use/Indications foruse</td><td colspan="1" rowspan="1">The ACE CK Reagent is intendedfor the quantitative determination ofcreatine kinase activity in serum.Measurement of creatine kinase isused in the diagnosis and treatmentof myocardial and muscle diseases ssuch as progressive, Duchenne-typemuscular dystrophy.</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Instrument/Platform</td><td colspan="1" rowspan="1">ACE Axcel Clinical ChemistrySystem</td><td colspan="1" rowspan="1">ACE Clinical ChemistrySystem</td></tr><tr><td colspan="1" rowspan="1">Basic Principle</td><td colspan="1" rowspan="1">Conversion of creatine phosphate tocreatine and ATP enzymaticallycoupled to the formation ofNADPH</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Sample Stability</td><td colspan="1" rowspan="1">4 hours at room temperature48 hours at -8 0C20 days below -20°C.</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">UnopenedStability</td><td colspan="1" rowspan="1">until the expiration date shown onthe box and bottle labels whenstored in the refrigerator at 2-8 °C</td><td colspan="1" rowspan="1">Same</td></tr></table>

# K. Standard/Guidance Document Referenced :

CLSI EP6-A Evaluation of the Linearity of Quantitative Measurement Procedures: A Statistical Approach (2003)   
CLSI EP5-A2 Evaluation of Precision Performance of Quantitative Measurement Methods; Second Edition (2004)   
CLSI EP7-A2 Interference Testing in Clinical Chemistry; Approved Guideline; Second Edition (2005)   
CLSI EP10-A3 Preliminary Evaluation of Quantitative Clinical Laboratory Measurement Procedures - Third Edition (2006)   
CLSI EP9-A2-IR Method Comparison and Bias Estimation Using Patient Samples; Approved Guideline- Second Edition (2002)   
CLSI EPI 17-A Protocol for Determination of Limits of Detection; Second Edition (2004)

# L. Test Principle:

The ACE BUN/Urea Reagent is a photometric assay in which urea in serum is hydrolyzed by urease to yield ammonia and carbon dioxide, the ammonia formed subsequently reacts with 2-oxoglutarate and NADH in the presence of glutamate dehydrogenase (GLDH) to yield glutamate and NAD. NADH absorbs strongly at $3 4 0 \mathrm { n m }$ , whereas $\mathrm { N A D } ^ { + }$ does not. The decrease in absorbance of NADH at $3 4 0 \mathrm { n m }$ is proportional to the urea concentration in the sample.

The ACE Creatinine Reagent is a photometric assay based on Jaffe reaction, in which serum creatinine reacts with picric acid in an alkaline medium to form a red-orange colored complex, which absorbs strongly at $5 0 5 \mathrm { n m }$ . The rate of complex formation is determined by the increase of absorbance at $5 0 5 \ \mathrm { n r n } / 5 7 3 \ \mathrm { n m }$ during a fixed time interval; this rate is directly proportional to the creatinine concentration in the sample.

The ACE Uric Acid Reagent is based on a photometric assay in which serum uric acid is oxidized by uricase to allantoin and hydrogen peroxide, which subsequently reacts to coupled chromogen dichlorohydroxybenzene sulfonic acid (DHBS) and 4-aminoantipyrine (AAP) in a reaction catalyzed by peroxidase and produces a red colored quinoneimine complex; which are measured by the increase in absorbance at $5 0 5 \ \mathrm { n m } / 6 1 0 \ \mathrm { n m }$ .

The ACE CK Reagent is a coupled enzymatic reaction in which serum creatine kinase (CK) first catalyzes the conversion of creatine phosphate and adenosine diphosphate (ADP) to creatine and ATP. Subsequently, hexokinase (HK) uses the ATP produced to phosphorylate D-glucose to form D-glucose-6-phosphate and ADP. In the final reaction, the enzyme glucose-6-phosphate dehydrogenase (G-6-PDH) uses D-glucose-6-phosphate to convert nicotinamide adenine dinucleotide phosphate $\mathrm { ( N A D P ^ { + } ) }$ into NADPH, absorbs strongly at $3 4 0 \mathrm { n m }$ . The rate of conversion of ${ \mathrm { N A D P + } }$ to NADPH, which is a function of the activity of CK in the sample, is determined by monitoring the increase in absorbance at $3 4 0 \ \mathrm { n m } / 3 7 8 \ \mathrm { n m }$

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility:

In-House: ACE BUN/Urea Reagent   
Four serum samples (three serum based pool and one normal human serum sample), were tested on one ACE Axcel Clinical Chemistry System two times per run, two runs per day, for a total of 20 or more days. The results are summarized in the table below:

<table><tr><td colspan="1" rowspan="1">Sample 1Mean 15.9 mg/dLBUN</td><td colspan="1" rowspan="1">WithinRun</td><td colspan="1" rowspan="1">BetweenRun</td><td colspan="1" rowspan="1">BetweenDay</td><td colspan="1" rowspan="1">Total</td></tr><tr><td colspan="1" rowspan="1">Standard Deviation,mg/dL</td><td colspan="1" rowspan="1">0.5</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">0.6</td><td colspan="1" rowspan="1">0.7</td></tr><tr><td colspan="1" rowspan="1">Coefficient ofVariation</td><td colspan="1" rowspan="1">2.9%</td><td colspan="1" rowspan="1">0.0%</td><td colspan="1" rowspan="1">3.5%</td><td colspan="1" rowspan="1">4.6%</td></tr><tr><td colspan="1" rowspan="1">Sample 2Mean 52.7 mg/dLBUN</td><td colspan="1" rowspan="1">WithinRun</td><td colspan="1" rowspan="1">BetweenRun</td><td colspan="1" rowspan="1">BetweenDay</td><td colspan="1" rowspan="1">Total</td></tr><tr><td colspan="1" rowspan="1">Standard Deviation,mg/dL</td><td colspan="1" rowspan="1">0.7</td><td colspan="1" rowspan="1">0.4</td><td colspan="1" rowspan="1">1.7</td><td colspan="1" rowspan="1">1.9</td></tr><tr><td colspan="1" rowspan="1">Coefficient ofVariation</td><td colspan="1" rowspan="1">1.3%</td><td colspan="1" rowspan="1">0.7%</td><td colspan="1" rowspan="1">3.3%</td><td colspan="1" rowspan="1">3.6%</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Sample 3Mean 87.6 mg/dLBUN</td><td rowspan=1 colspan=1>WithinRun</td><td rowspan=1 colspan=1>BetweenRun</td><td rowspan=1 colspan=1>BetweenDay</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Standard Deviation,mg/dL</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>2.7</td><td rowspan=1 colspan=1>3.0</td></tr><tr><td rowspan=1 colspan=1>Coefficient ofVariation</td><td rowspan=1 colspan=1>1.1%</td><td rowspan=1 colspan=1>1.2%</td><td rowspan=1 colspan=1>3.1%</td><td rowspan=1 colspan=1>3.5%</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Sample 4Mean 8.0 mg/dLBUN</td><td rowspan=1 colspan=1>WithinRun</td><td rowspan=1 colspan=1>BetweenRun</td><td rowspan=1 colspan=1>BetweenDay</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Standard Deviation,mg/dL</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>0.3</td></tr><tr><td rowspan=1 colspan=1>Coefficient ofVariation</td><td rowspan=1 colspan=1>3.3%</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>2.7%</td><td rowspan=1 colspan=1>4.3%</td></tr></table>

# Point of Care Laboratory: ACE BUN/Urea Reagent

Three serum based samples were tested on three ACE Axcel Clinical Chemistry Systems (one at each POL site) at least three times per run, one run per day, for a total of 5 days. The mean, standard deviations and $\%$ coefficients of variation (CV) were calculated for each sample.

<table><tr><td rowspan=1 colspan=3>BUN/Urea</td><td rowspan=1 colspan=2>Within-Run</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>Lab</td><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean(mg/dL)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>POL 1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>14.8</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>3.0%</td></tr><tr><td rowspan=1 colspan=1>POL 2</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>16.1</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>1.9%</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>3.4%</td></tr><tr><td rowspan=1 colspan=1>POL 3</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>15.1</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>2.6%</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>5.2%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>POL 1</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>48.9</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>0.6%</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>3.5%</td></tr><tr><td rowspan=1 colspan=1>POL 2</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>52.9</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>0.8%</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>3.2%</td></tr><tr><td rowspan=1 colspan=1>POL 3</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>49.2</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>1.2%</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>3.1%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>POL 1</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>82.3</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>0.6%</td><td rowspan=1 colspan=1>2.6</td><td rowspan=1 colspan=1>3.2%</td></tr><tr><td rowspan=1 colspan=1>POL 2</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>87.7</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>0.6%</td><td rowspan=1 colspan=1>2.9</td><td rowspan=1 colspan=1>3.3%</td></tr><tr><td rowspan=1 colspan=1>POL 3</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>83.1</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>1.0%</td><td rowspan=1 colspan=1>4.1</td><td rowspan=1 colspan=1>4.9%</td></tr></table>

# In-House: ACE Creatinine Reagent

Four serum samples, three serum based pool and one normal human serum sample, were tested on one ACE Axcel Clinical Chemistry System two times per run, two runs per day, for a total of 22 days. The results are summarized in the table below:

<table><tr><td rowspan=1 colspan=1>Sample 1Mean 1.005 mg/dLCreatinine</td><td rowspan=1 colspan=1>WithinRun</td><td rowspan=1 colspan=1>BetweenRun</td><td rowspan=1 colspan=1>BetweenDay</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Standard Deviation,mg/dL</td><td rowspan=1 colspan=1>0.053</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.029</td><td rowspan=1 colspan=1>0.060</td></tr><tr><td rowspan=1 colspan=1>Coefficient ofVariation</td><td rowspan=1 colspan=1>5.3%</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>2.8%</td><td rowspan=1 colspan=1>6.0%</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Sample 2Mean 8.366 mg/dLCreatinine</td><td rowspan=1 colspan=1>WithinRun</td><td rowspan=1 colspan=1>BetweenRun</td><td rowspan=1 colspan=1>BetweenDay</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Standard Deviation,mg/dL</td><td rowspan=1 colspan=1>0.109</td><td rowspan=1 colspan=1>0.158</td><td rowspan=1 colspan=1>0.132</td><td rowspan=1 colspan=1>0.233</td></tr><tr><td rowspan=1 colspan=1>Coefficient ofVariation</td><td rowspan=1 colspan=1>1.3%</td><td rowspan=1 colspan=1>1.9%</td><td rowspan=1 colspan=1>1.6%</td><td rowspan=1 colspan=1>2.8%</td></tr></table>

<table><tr><td colspan="1" rowspan="1">Sample 3Mean 15.868 mg/dLCreatinine</td><td colspan="1" rowspan="1">WithinRun</td><td colspan="1" rowspan="1">BetweenRun</td><td colspan="1" rowspan="1">BetweenDay</td><td colspan="1" rowspan="1">Total</td></tr><tr><td colspan="1" rowspan="1">Standard Deviation,mg/dL</td><td colspan="1" rowspan="1">0.224</td><td colspan="1" rowspan="1">0.132</td><td colspan="1" rowspan="1">0.350</td><td colspan="1" rowspan="1">0.436</td></tr><tr><td colspan="1" rowspan="1">Coefficient ofVariation</td><td colspan="1" rowspan="1">1.4%</td><td colspan="1" rowspan="1">0.8%</td><td colspan="1" rowspan="1">2.2%</td><td colspan="1" rowspan="1">2.7%</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Sample 4Mean 0.556 mg/dLCreatinine</td><td rowspan=1 colspan=1>WithinRun</td><td rowspan=1 colspan=1>BetweenRun</td><td rowspan=1 colspan=1>BetweenDay</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Standard Deviation,mg/dL</td><td rowspan=1 colspan=1>0.054</td><td rowspan=1 colspan=1>0.009</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.054</td></tr><tr><td rowspan=1 colspan=1>Coefficient ofVariation</td><td rowspan=1 colspan=1>9.6%</td><td rowspan=1 colspan=1>1.6%</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>9.8%</td></tr></table>

# Point of Care Laboratory: ACE Creatinine Reagent

Four serum based samples, three serum-based pools and one normal human serum pool were tested on three ACE Axcel Clinical Chemistry Systems (one at each POL site) at least three times per run, one run per day, for a total of 5 days. The mean, standard deviations and $\%$ coefficients of variation (CV) were calculated for each sample.

<table><tr><td rowspan=1 colspan=3>Creatinine</td><td rowspan=1 colspan=2>Within-Run</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>Lab</td><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean(mg/dL)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>POL 1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1.000</td><td rowspan=1 colspan=1>0.038</td><td rowspan=1 colspan=1>3.8%</td><td rowspan=1 colspan=1>0.040</td><td rowspan=1 colspan=1>4.0%</td></tr><tr><td rowspan=1 colspan=1>POL 2</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0.941</td><td rowspan=1 colspan=1>0.048</td><td rowspan=1 colspan=1>5.1%</td><td rowspan=1 colspan=1>0.058</td><td rowspan=1 colspan=1>6.1%</td></tr><tr><td rowspan=1 colspan=1>POL 3</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0.967</td><td rowspan=1 colspan=1>0.032</td><td rowspan=1 colspan=1>3.3%</td><td rowspan=1 colspan=1>0.051</td><td rowspan=1 colspan=1>5.3%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>POL 1</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>8.469</td><td rowspan=1 colspan=1>0.120</td><td rowspan=1 colspan=1>1.4%</td><td rowspan=1 colspan=1>0.222</td><td rowspan=1 colspan=1>2.6%</td></tr><tr><td rowspan=1 colspan=1>POL 2</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>8.639</td><td rowspan=1 colspan=1>0.115</td><td rowspan=1 colspan=1>1.3%</td><td rowspan=1 colspan=1>0.179</td><td rowspan=1 colspan=1>2.1%</td></tr><tr><td rowspan=1 colspan=1>POL 3</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>8.215</td><td rowspan=1 colspan=1>0.094</td><td rowspan=1 colspan=1>1.1%</td><td rowspan=1 colspan=1>0.200</td><td rowspan=1 colspan=1>2.4%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>POL 1</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>16.262</td><td rowspan=1 colspan=1>0.254</td><td rowspan=1 colspan=1>1.6%</td><td rowspan=1 colspan=1>0.486</td><td rowspan=1 colspan=1>3.0%</td></tr><tr><td rowspan=1 colspan=1>POL 2</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>16.485</td><td rowspan=1 colspan=1>0.175</td><td rowspan=1 colspan=1>1.1%</td><td rowspan=1 colspan=1>0.367</td><td rowspan=1 colspan=1>2.2%</td></tr><tr><td rowspan=1 colspan=1>POL 3</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>15.773</td><td rowspan=1 colspan=1>0.144</td><td rowspan=1 colspan=1>0.9%</td><td rowspan=1 colspan=1>0.334</td><td rowspan=1 colspan=1>2.1%</td></tr></table>

In-House: ACE Uric Acid Reagent Four serum samples, (three serum based pool and one normal human serum sample), were tested on one ACE Axcel Clinical Chemistry System two times per run, two runs per day, for a total of 22 days. The results are summarized in the table below:

<table><tr><td rowspan=1 colspan=1>Sample 1Mean 2.90 mg/dLUric Acid</td><td rowspan=1 colspan=1>WithinRun</td><td rowspan=1 colspan=1>BetweenRun</td><td rowspan=1 colspan=1>BetweenDay</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Standard Deviation,mg/dL</td><td rowspan=1 colspan=1>0.14</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>0.16</td></tr><tr><td rowspan=1 colspan=1>Coefficient ofVariation</td><td rowspan=1 colspan=1>4.9%</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>2.1%</td><td rowspan=1 colspan=1>5.4%</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Sample 2Mean 7.74 mg/dLUric Acid</td><td rowspan=1 colspan=1>WithinRun</td><td rowspan=1 colspan=1>BetweenRun</td><td rowspan=1 colspan=1>BetweenDay</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Standard Deviation,mg/dL</td><td rowspan=1 colspan=1>0.18</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.08</td><td rowspan=1 colspan=1>0.20</td></tr><tr><td rowspan=1 colspan=1>Coefficient ofVariation</td><td rowspan=1 colspan=1>2.4%</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>1.1%</td><td rowspan=1 colspan=1>2.6%</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Sample 3Mean 12.34 mg/dLUric Acid</td><td rowspan=1 colspan=1>WithinRun</td><td rowspan=1 colspan=1>BetweenRun</td><td rowspan=1 colspan=1>BetweenDay</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Standard Deviation,mg/dL</td><td rowspan=1 colspan=1>0.23</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.10</td><td rowspan=1 colspan=1>0.25</td></tr><tr><td rowspan=1 colspan=1>Coefficient ofVariation</td><td rowspan=1 colspan=1>1.8%</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.8%</td><td rowspan=1 colspan=1>2.0%</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Sample 4Mean 4.02 mg/dLUric Acid</td><td rowspan=1 colspan=1>WithinRun</td><td rowspan=1 colspan=1>BetweenRun</td><td rowspan=1 colspan=1>BetweenDay</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Standard Deviation,mg/dL</td><td rowspan=1 colspan=1>0.10</td><td rowspan=1 colspan=1>0.08</td><td rowspan=1 colspan=1>0.08</td><td rowspan=1 colspan=1>0.15</td></tr><tr><td rowspan=1 colspan=1>Coefficient ofVariation</td><td rowspan=1 colspan=1>2.6%</td><td rowspan=1 colspan=1>2.0%</td><td rowspan=1 colspan=1>2.0%</td><td rowspan=1 colspan=1>3.8%</td></tr></table>

# Point of Care Laboratory: ACE Uric Acid Reagent

Four serum based samples, three serum-based pools and one normal human serum pool were tested on three ACE Axcel Clinical Chemistry Systems (one at each POL site) at least three times per run, one run per day, for a total of 5 days. The mean, standard deviations and $\%$ coefficients of variation (CV) were calculated for each sample.

<table><tr><td rowspan=1 colspan=3>Uric Acid</td><td rowspan=1 colspan=2>Within-Run</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>Lab</td><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean(mg/dL)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>POL 1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>2.74</td><td rowspan=1 colspan=1>0.12</td><td rowspan=1 colspan=1>4.4%</td><td rowspan=1 colspan=1>0.14</td><td rowspan=1 colspan=1>5.2%</td></tr><tr><td rowspan=1 colspan=1>POL 2</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>2.95</td><td rowspan=1 colspan=1>0.09</td><td rowspan=1 colspan=1>3.0%</td><td rowspan=1 colspan=1>0.09</td><td rowspan=1 colspan=1>3.0%</td></tr><tr><td rowspan=1 colspan=1>POL 3</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>2.84</td><td rowspan=1 colspan=1>0.10</td><td rowspan=1 colspan=1>3.6%</td><td rowspan=1 colspan=1>0.10</td><td rowspan=1 colspan=1>3.6%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>POL 1</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>7.65</td><td rowspan=1 colspan=1>0.15</td><td rowspan=1 colspan=1>2.0%</td><td rowspan=1 colspan=1>0.17</td><td rowspan=1 colspan=1>2.2%</td></tr><tr><td rowspan=1 colspan=1>POL 2</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>7.69</td><td rowspan=1 colspan=1>0.29</td><td rowspan=1 colspan=1>3.8%</td><td rowspan=1 colspan=1>0.29</td><td rowspan=1 colspan=1>3.8%</td></tr><tr><td rowspan=1 colspan=1>POL 3</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>7.78</td><td rowspan=1 colspan=1>0.14</td><td rowspan=1 colspan=1>1.8%</td><td rowspan=1 colspan=1>0.14</td><td rowspan=1 colspan=1>1.8%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>POL 1</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>12.45</td><td rowspan=1 colspan=1>0.19</td><td rowspan=1 colspan=1>1.5%</td><td rowspan=1 colspan=1>0.29</td><td rowspan=1 colspan=1>2.3%</td></tr><tr><td rowspan=1 colspan=1>POL 2</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>12.53</td><td rowspan=1 colspan=1>0.26</td><td rowspan=1 colspan=1>2.1%</td><td rowspan=1 colspan=1>0.26</td><td rowspan=1 colspan=1>2.1%</td></tr><tr><td rowspan=1 colspan=1>POL 3</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>12.55</td><td rowspan=1 colspan=1>0.23</td><td rowspan=1 colspan=1>1.8%</td><td rowspan=1 colspan=1>0.23</td><td rowspan=1 colspan=1>1.8%</td></tr></table>

# In-House: ACE CK Reagent

Four serum samples, three serum based pool and one normal human serum sample, were tested on one ACE Axcel Clinical Chemistry System two times per run, two runs per day, for a total of 22 days. The results are summarized in the table below:

<table><tr><td rowspan=1 colspan=1>Sample 1Mean 84.9 U/LCreatine Kinase</td><td rowspan=1 colspan=1>WithinRun</td><td rowspan=1 colspan=1>BetweenRun</td><td rowspan=1 colspan=1>BetweenDay</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Standard Deviation,U/L</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>2.6</td></tr><tr><td rowspan=1 colspan=1>Coefficient of Variation</td><td rowspan=1 colspan=1>2.9%</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.8%</td><td rowspan=1 colspan=1>3.0%</td></tr></table>

<table><tr><td colspan="1" rowspan="1">Sample 2Mean 658.8 U/LCreatine Kinase</td><td colspan="1" rowspan="1">WithinRun</td><td colspan="1" rowspan="1">BetweenRun</td><td colspan="1" rowspan="1">BetweenDay</td><td colspan="1" rowspan="1">Total</td></tr><tr><td colspan="1" rowspan="1">Standard Deviation,U/L</td><td colspan="1" rowspan="1">11.5</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">6.1</td><td colspan="1" rowspan="1">13.0</td></tr><tr><td colspan="1" rowspan="1">Coefficient of Variation</td><td colspan="1" rowspan="1">1.7%</td><td colspan="1" rowspan="1">0.0%</td><td colspan="1" rowspan="1">0.9%</td><td colspan="1" rowspan="1">2.0%</td></tr><tr><td colspan="1" rowspan="1">Sample 3Mean 1182.9 U/LCreatine Kinase</td><td colspan="1" rowspan="1">WithinRun</td><td colspan="1" rowspan="1">BetweenRun</td><td colspan="1" rowspan="1">BetweenDay</td><td colspan="1" rowspan="1">Total</td></tr><tr><td colspan="1" rowspan="1">Standard Deviation,U/L</td><td colspan="1" rowspan="1">13.4</td><td colspan="1" rowspan="1">10.3</td><td colspan="1" rowspan="1">9.1</td><td colspan="1" rowspan="1">19.2</td></tr><tr><td colspan="1" rowspan="1">Coefficient of Variation</td><td colspan="1" rowspan="1">1.1%</td><td colspan="1" rowspan="1">0.9%</td><td colspan="1" rowspan="1">0.8%</td><td colspan="1" rowspan="1">1.6%</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Sample 4Mean 99.1 U/LCreatine Kinase</td><td rowspan=1 colspan=1>WithinRun</td><td rowspan=1 colspan=1>BetweenRun</td><td rowspan=1 colspan=1>BetweenDay</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Standard Deviation,U/L</td><td rowspan=1 colspan=1>5.2</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>5.4</td></tr><tr><td rowspan=1 colspan=1>Coefficient of Variation</td><td rowspan=1 colspan=1>5.2%</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>1.6%</td><td rowspan=1 colspan=1>5.5%</td></tr></table>

# Point of Care Laboratory: ACE CK Reagent

Four serum based samples, three serum-based pools and one normal human serum pool were tested on three ACE Axcel Clinical Chemistry Systems (one at each POL site) at least three times per run, one run per day, for a total of 5 days. The mean, standard deviations and $\%$ coefficients of variation (CV) were calculated for each sample.

<table><tr><td rowspan=1 colspan=3>Creatine Kinase</td><td rowspan=1 colspan=2>Within-Run</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>Lab</td><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean(U/L)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>POL 1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>82.1</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>2.7%</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>2.7%</td></tr><tr><td rowspan=1 colspan=1>POL 2</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>86.8</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>2.8%</td><td rowspan=1 colspan=1>3.9</td><td rowspan=1 colspan=1>4.5%</td></tr><tr><td rowspan=1 colspan=1>POL 3</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>83.6</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>1.7%</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>2.2%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>POL 1</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>618.3</td><td rowspan=1 colspan=1>23.0</td><td rowspan=1 colspan=1>3.7%</td><td rowspan=1 colspan=1>29.5</td><td rowspan=1 colspan=1>4.8%</td></tr><tr><td rowspan=1 colspan=1>POL 2</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>659.4</td><td rowspan=1 colspan=1>9.6</td><td rowspan=1 colspan=1>1.5%</td><td rowspan=1 colspan=1>20.8</td><td rowspan=1 colspan=1>3.2%</td></tr><tr><td rowspan=1 colspan=1>POL 3</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>636.4</td><td rowspan=1 colspan=1>15.5</td><td rowspan=1 colspan=1>2.4%</td><td rowspan=1 colspan=1>15.7</td><td rowspan=1 colspan=1>2.5%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>POL 1</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>1123.0</td><td rowspan=1 colspan=1>20.4</td><td rowspan=1 colspan=1>1.8%</td><td rowspan=1 colspan=1>21.1</td><td rowspan=1 colspan=1>1.9%</td></tr><tr><td rowspan=1 colspan=1>POL 2</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>1170.5</td><td rowspan=1 colspan=1>26.7</td><td rowspan=1 colspan=1>2.3%</td><td rowspan=1 colspan=1>3.6</td><td rowspan=1 colspan=1>3.1%</td></tr><tr><td rowspan=1 colspan=1>POL 3</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>1153.5</td><td rowspan=1 colspan=1>15.3</td><td rowspan=1 colspan=1>1.3%</td><td rowspan=1 colspan=1>18.1</td><td rowspan=1 colspan=1>1.6%</td></tr></table>

# b. Linearity/assay reportable range:

# ACE BUN/ Urea Reagent

Linearity studies were carried out using dilutions of a spiked serum samples. Twelve concentrations were prepared by mixing spiked serum samples in known proportion with saline. All samples were measured in triplicate. The sample range tested was 0.03 to $1 0 0 . 3 ~ \mathrm { m g / d L }$ . The linear regression between the expected values and the measured values yield the following correlations:

<table><tr><td rowspan=1 colspan=1>Claimed Measuring Range</td><td rowspan=1 colspan=1>Intercept</td><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>$r2}$</td></tr><tr><td rowspan=1 colspan=1>2 to 100 mg/dL</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>0.994</td><td rowspan=1 colspan=1>0.9984</td></tr></table>

Based on the linearity data, the measuring range claimed from 2 to $1 0 0 \mathrm { m g / d L }$ was supported.

# ACE Creatinine Reagent

Linearity studies were carried out using dilutions of a spiked serum samples.

Fourteen concentrations were prepared by mixing spiked serum samples in known proportion with saline. All samples were measured in triplicate. The sample range tested was 0.12 to $2 4 . 7 5 \ : \mathrm { m g / d L }$ . The linear regression between the expected values and the measured values yield the following correlations:

<table><tr><td rowspan=1 colspan=1>Claimed Measuring Range</td><td rowspan=1 colspan=1>−Intercept</td><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>b2}$</td></tr><tr><td rowspan=1 colspan=1>0.23 to 25.0 mg/dL</td><td rowspan=1 colspan=1>0.05</td><td rowspan=1 colspan=1>0.990</td><td rowspan=1 colspan=1>0.9996</td></tr></table>

Based on the linearity data, the measuring range claimed from 0.23 to $2 5 . 0 \ : \mathrm { m g / d L }$ was supported.

# ACE Uric Acid Reagent

Linearity studies were carried out using dilutions of a spiked serum samples.

Fourteen concentrations were prepared by mixing spiked serum samples in known proportion with saline. All samples were measured in triplicate. The sample range tested was 0.43 to $1 7 . 4 3 ~ \mathrm { m g / d L }$ . The linear regression between the expected values and the measured values yield the following correlations:

<table><tr><td rowspan=1 colspan=1>Claimed Measuring Range Intercept</td><td rowspan=1 colspan=1>Intercept</td><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>r2}$</td></tr><tr><td rowspan=1 colspan=1>1.2 to 16.0 mg/dL</td><td rowspan=1 colspan=1>-0.16</td><td rowspan=1 colspan=1>0.968</td><td rowspan=1 colspan=1>0.9964</td></tr></table>

Based on the linearity data, the measuring range claimed from 1.2 to $1 6 . 0 \ : \mathrm { m g / d L }$ was supported

# ACE CK Reagent

Linearity studies were carried out using dilutions of a spiked serum samples. Eight concentrations were prepared by mixing spiked serum samples in known proportion with saline. All samples were measured in triplicate. The sample range tested was 3.5 to $1 5 4 7 . 5 \mathrm { U / L }$ . The linear regression between the expected values and the measured values yield the following correlations:

<table><tr><td rowspan=1 colspan=1>Claimed Measuring Range</td><td rowspan=1 colspan=1>Intercept</td><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>r2}$</td></tr><tr><td rowspan=1 colspan=1>11 to 1350 U/L</td><td rowspan=1 colspan=1>-0.363</td><td rowspan=1 colspan=1>0.9987</td><td rowspan=1 colspan=1>0.9997</td></tr></table>

Based on the linearity data, the measuring range claimed from 11 to $1 3 5 0 \mathrm { U / L }$ was supported.

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

# Traceability:

GEMCAL Reference Serum is traceable to NIST SRM 909 for BUN and uric acid and IDMS traceable to the NIST SRM 967 for creatinine.

For ACE CK reagent, enzyme activity (in IU/L) is determined directly by multiplying the absorbance change per minute of the unknown sample by a factor (10956) derived from the molar absorptivity of NADPH.

# On-Board stability:

On-board stability studies were performed for all reagents by the sponsor. The stability protocols and acceptance criteria were reviewed and determined to be adequate. All ACE reagents in this submission demonstrated the on-board stability as stated in the table below when stored in the ACE Axcel reagent chamber (at $1 0 { - } 1 4 ^ { \circ } \mathrm { C } )$ with Evap-Caps.

<table><tr><td rowspan=2 colspan=1>Reagent</td><td rowspan=1 colspan=1>ACE Axcel On-Board</td></tr><tr><td rowspan=1 colspan=1>Stability (Days)</td></tr><tr><td rowspan=1 colspan=1>BUN</td><td rowspan=1 colspan=1>30</td></tr><tr><td rowspan=1 colspan=1>Creatinine</td><td rowspan=1 colspan=1>10</td></tr><tr><td rowspan=1 colspan=1>Uric Acid</td><td rowspan=1 colspan=1>30</td></tr><tr><td rowspan=1 colspan=1>Creatinine Kinase</td><td rowspan=1 colspan=1>25</td></tr></table>

# d. Detection limit:

Detection limit studies (LoB, LoD, and LoQ) were performed in accordance with CLSI Guidance Document EP17-A. For LoB and LoD, testing was carried out using blanks and low samples (total of 60 replicates each sample) over three days on two ACE Axcel Clinical Chemistry Systems. LoQ testing was performed using 5 low samples (total of 40 replicates for each sample). A curve was fit to estimate the relationship between the measured value and the $\% \mathrm { C V }$ . LoQ is defined as the lowest concentration for which the imprecision $\% C V$ is $\leq 2 0 \%$ .

The sponsor’s claimed detection limits for the four analytes are summarized below:

<table><tr><td rowspan=1 colspan=1>Reagent</td><td rowspan=1 colspan=1>Limit of Blank(LoB)</td><td rowspan=1 colspan=1>Limit ofDetection(LoD)</td><td rowspan=1 colspan=1>Limit ofQuantification(LoQ)</td></tr><tr><td rowspan=1 colspan=1>BUN</td><td rowspan=1 colspan=1>0.9 mg/dL</td><td rowspan=1 colspan=1>1.1 mg/dL</td><td rowspan=1 colspan=1>1.9 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Creatinine</td><td rowspan=1 colspan=1>0.141 mg/dL</td><td rowspan=1 colspan=1>0.19mg/dL</td><td rowspan=1 colspan=1>0.23 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Uric Acid</td><td rowspan=1 colspan=1>0.97mg/dL</td><td rowspan=1 colspan=1>1.13mg/dL</td><td rowspan=1 colspan=1>1.2 mg/dL</td></tr><tr><td rowspan=1 colspan=1>CK</td><td rowspan=1 colspan=1>3.2 U/L</td><td rowspan=1 colspan=1>3.5 U/L</td><td rowspan=1 colspan=1>10.6 U/L</td></tr></table>

The sponsor’s claimed measuring range for BUN is 2 to $1 0 0 \mathrm { m g / d L }$ , for creatinine is 0.23 to $2 5 . 0 \ : \mathrm { m g / d L }$ , for uric acid is 1.2 to $1 6 . 0 \ : \mathrm { m g / d L }$ , and for CK is 11 to $1 3 5 0 \mathrm { U / L }$ .

# e. Analytical specificity:

# ACE BUN/ Urea Reagent

Interference studies were performed by using two serum pools containing $2 0 \mathrm { m g / d L }$ and $5 0 \mathrm { m g / d L }$ BUN with individual interferents at a range of concentrations. The sera were assayed for BUN $\mathbf { \tilde { n } } = 3$ replicates) and the mean result calculated. Interference was considered to be significant by the sponsor if the analyte recovery changed by $\pm$ $10 \%$ . The results reported were obtained on the ACE Axcel Clinical Chemistry System analyzer.

<table><tr><td rowspan=1 colspan=1>Interferent</td><td rowspan=1 colspan=1>No Significant Interference At or Below:</td></tr><tr><td rowspan=1 colspan=1>Unconjugated Bilirubin</td><td rowspan=1 colspan=1>54 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Hemolysis</td><td rowspan=1 colspan=1>1000 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Lipemia (Intralipid)</td><td rowspan=1 colspan=1>1000 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Ascorbic Acid</td><td rowspan=1 colspan=1>6 mg/dL</td></tr></table>

# ACE Creatinine Reagent

Interference studies were performed by using two serum pools containing $1 \mathrm { m g / d L }$ and $9 \mathrm { m g / d L }$ creatinine with individual interferents at a range of concentrations. The sera were assayed for creatinine $\mathrm { \acute { n } } = 3$ replicates) and the mean result calculated. Interference was considered to be significant by the sponsor if the analyte recovery changed $6 \mathrm { y } \pm 1 0 \%$ . The results reported were obtained on the ACE Axcel Clinical Chemistry System analyzer.

<table><tr><td rowspan=1 colspan=1>Interferent</td><td rowspan=1 colspan=1>No Significant Interference At or Below:</td></tr><tr><td rowspan=1 colspan=1>Unconjugated Bilirubin</td><td rowspan=1 colspan=1>6.2 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Hemolysis</td><td rowspan=1 colspan=1>500 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Lipemia (Intralipid)</td><td rowspan=1 colspan=1>1000 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Ascorbic Acid</td><td rowspan=1 colspan=1>6 mg/dL</td></tr></table>

# ACE Uric Acid Reagent

Interference studies were performed by using two serum pools containing $4 \mathrm { m g / d L }$ and $1 1 \mathrm { m g / d L }$ uric acid with individual interferents at a range of concentrations. The sera were assayed for uric acid $\mathrm { \acute { n } } = 3$ replicates) and the mean result calculated. Interference was considered to be significant by the sponsor if the analyte recovery changed b $\mathrm { { y } \pm 1 0 \% }$ . The results reported were obtained on the ACE Axcel Clinical Chemistry System analyzer.

<table><tr><td rowspan=1 colspan=1>Interferent</td><td rowspan=1 colspan=1>No Significant Interference At or Below:</td></tr><tr><td rowspan=1 colspan=1>Unconjugated Bilirubin</td><td rowspan=1 colspan=1>32 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Hemolysis</td><td rowspan=1 colspan=1>62.5 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Triglycerides</td><td rowspan=1 colspan=1>325 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Ascorbic Acid</td><td rowspan=1 colspan=1>1.34 mg/dL</td></tr></table>

The sponsor has the following limitation in the labeling due to hemoglobin interference, “Hemolyzed samples cannot be used. Use clear, unhemolyzed sample.”

For ascorbic acid, the following limitation was noted in the labeling: “ Ascorbic acid concentrations as low as 1.3 mg/dL have been shown to interfere with this assay. Non-fasting patients taking a high dose of vitamin $C$ may cause low uric acid levels and results should be interpreted with caution.”

# ACE CK Reagent

Interference studies were performed by using two serum pools containing $1 0 0 \mathrm { U / L }$ and $6 0 0 \mathrm { U / L }$ creatine kinase with individual interferents at a range of concentrations. The sera were assayed for creatine kinase $\mathrm { \acute { n } } = 3$ replicates) and the mean result calculated. Interference was considered to be significant by the sponsor if the analyte recovery changed b $\mathrm { y } \pm 1 0 \%$ . The results reported were obtained on the ACE Axcel

Clinical Chemistry System analyzer.

<table><tr><td rowspan=1 colspan=1>Interferent</td><td rowspan=1 colspan=1>No Significant Interference At or Below:</td></tr><tr><td rowspan=1 colspan=1>Unconjugated Bilirubin</td><td rowspan=1 colspan=1>28 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Hemolysis</td><td rowspan=1 colspan=1>125 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Lipemia (Intralipid)</td><td rowspan=1 colspan=1>1000 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Ascorbic Acid</td><td rowspan=1 colspan=1>6 mg/dL</td></tr></table>

The sponsor has the following limitation in the labeling due to hemoglobin interference, “Hemolyzed samples cannot be used. Use clear, unhemolyzed sample.”

f. Assay cut-off: Not applicable

2. Comparison studies:

Studies were carried out according to CLSI EP09-A2-IR.

In house: ACE BUN/ Urea Reagent

One hundred thirteen serum samples were assayed in parallel by both the candidate and predicate methods. The results were analyzed by using Deming regression. The range tested was 4 to $9 6 \mathrm { m g / d L }$ . Altered samples were included in the study (no more than $1 0 \%$ ).

The comparison by Deming regression resulted in a slope of 1.012 $( 9 5 \% C \mathrm { I } = 0 . 9 9 5$ to 1.028), an intercept of 0.2 $9 5 \% C \mathrm { I } = - 0 . 3$ to 0.6), correlation coefficient $( \mathrm { R } ^ { 2 } ) = 0 . 9 9 6 3$ , and a standard error of 1.5.

# Point of Care Laboratory: ACE BUN/ Urea Reagent

Serum samples were assayed in parallel by both the candidate and predicate methods at three POC sites. The results were analyzed by using Deming regression. (Some altered samples were used among all three sites.)

<table><tr><td rowspan=1 colspan=1>POL</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Range</td><td rowspan=1 colspan=1>RegressionEquation</td><td rowspan=1 colspan=1>CorrelationCoefficient</td><td rowspan=1 colspan=1>StandardError</td><td rowspan=1 colspan=1>ConfidenceIntervalSlope</td><td rowspan=1 colspan=1>ConfidenceIntervalIntercept</td></tr></table>

In house: ACE Creatinine Reagent   

<table><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>59</td><td rowspan=1 colspan=1>4-97</td><td rowspan=1 colspan=1>y = 0.996x -0.3</td><td rowspan=1 colspan=1>0.9988</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>0.983 to1.009</td><td rowspan=1 colspan=1>-0.7 to 0.1</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>2-100</td><td rowspan=1 colspan=1>y = 1.022x+ 0.6</td><td rowspan=1 colspan=1>0.9982</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>1.003 to1.038</td><td rowspan=1 colspan=1>-0.1 to 1.2</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>3-98</td><td rowspan=1 colspan=1>y = 1.020x+1.1</td><td rowspan=1 colspan=1>0.9987</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>1.004 to1.036</td><td rowspan=1 colspan=1>0.5 to 1.6</td></tr></table>

One hundred thirty six serum samples were assayed in parallel by both the candidate and predicate methods. The results were analyzed by using Deming regression. The range tested was 0.28 to $2 2 . 9 5 ~ \mathrm { m g / d L }$ . Altered samples were included in the study (no more than $1 0 \%$ ).

The comparison by Deming regression resulted in a slope of 0.979 $9 5 \% C \mathrm { I } = 0 . 9 7 5$ to 0.983), an intercept of - 0.006 $( 9 5 \% C \mathrm { I } = - 0 . 0 2 2$ to 0.010), correlation coefficient $( \mathsf { R } ^ { 2 } ) =$ 0.9998, and a standard error of 0.082.

# Point of Care Laboratory: ACE Creatinine Reagent

Serum samples were assayed in parallel by both the candidate and predicate methods at three POC sites. The results were analyzed by using Deming regression. (Some altered samples were used among all three sites.)

In house: ACE Uric acid Reagent   

<table><tr><td rowspan=1 colspan=1>POL</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Range</td><td rowspan=1 colspan=1>RegressionEquation</td><td rowspan=1 colspan=1>CorrelationCoefficient</td><td rowspan=1 colspan=1>StandardError</td><td rowspan=1 colspan=1>ConfidenceIntervalSlope</td><td rowspan=1 colspan=1>ConfidenceIntervalIntercept</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>62</td><td rowspan=1 colspan=1>0.34-24.29</td><td rowspan=1 colspan=1>y = 1.022x -0.036</td><td rowspan=1 colspan=1>0.9998</td><td rowspan=1 colspan=1>0.123</td><td rowspan=1 colspan=1>1.016 to1.027</td><td rowspan=1 colspan=1>-0.072 to0.001</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>68</td><td rowspan=1 colspan=1>0.47-22.98</td><td rowspan=1 colspan=1>y = 0.969x -0.040</td><td rowspan=1 colspan=1>0.9995</td><td rowspan=1 colspan=1>0.129</td><td rowspan=1 colspan=1>0.961 to0.976</td><td rowspan=1 colspan=1>-0.077 to -0.004</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>52</td><td rowspan=1 colspan=1>0.65-22.28</td><td rowspan=1 colspan=1>y = 1.006x -0.073</td><td rowspan=1 colspan=1>0.9994</td><td rowspan=1 colspan=1>0.192</td><td rowspan=1 colspan=1>0.996 to1.015</td><td rowspan=1 colspan=1>-0.136 to -0.009</td></tr></table>

One hundred and six serum samples were assayed in parallel by both the candidate and predicate methods. The results were analyzed by using Deming regression. The range tested was 1.7 to $1 5 . 9 \mathrm { m g / d L }$ . Altered samples were included in the study (no more than $1 0 \%$ ).

The comparison by Deming regression resulted in a slope of 1.042 $( 9 5 \% C \mathrm { I } = 1 . 0 2 3$ to 1.060), an intercept of - 0.06 $9 5 \% C \mathrm { I } = - 0 . 1 8$ to 0.07), correlation coefficient $( \mathsf { R } ^ { 2 } ) =$ 0.9958, and a standard error of 0.23.

# Point of Care Laboratory: ACE Uric acid Reagent

Serum samples were assayed in parallel by both the candidate and predicate methods at three POC sites. The results were analyzed by using Deming regression. (Some altered samples were used among all three sites.)

<table><tr><td rowspan=1 colspan=1>POL</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Range</td><td rowspan=1 colspan=1>RegressionEquation</td><td rowspan=1 colspan=1>CorrelationCoefficient</td><td rowspan=1 colspan=1>StandardError</td><td rowspan=1 colspan=1>ConfidenceIntervalSlope</td><td rowspan=1 colspan=1>ConfidenceIntervalIntercept</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>52</td><td rowspan=1 colspan=1>1.4-15.6</td><td rowspan=1 colspan=1>y = 1.024x -0.11</td><td rowspan=1 colspan=1>0.9961</td><td rowspan=1 colspan=1>0.25</td><td rowspan=1 colspan=1>0.998 to1.050</td><td rowspan=1 colspan=1>-0.28 to0.05</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>72</td><td rowspan=1 colspan=1>2.1-13.6</td><td rowspan=1 colspan=1>y = 1.013x -0.02</td><td rowspan=1 colspan=1>0.9858</td><td rowspan=1 colspan=1>0.44</td><td rowspan=1 colspan=1>0.972 to1.053</td><td rowspan=1 colspan=1>-0.31 to0.28</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>2.4-15.8</td><td rowspan=1 colspan=1>y = 1.026x -0.08</td><td rowspan=1 colspan=1>0.9961</td><td rowspan=1 colspan=1>0.22</td><td rowspan=1 colspan=1>0.998 to1.054</td><td rowspan=1 colspan=1>-0.27 to0.11</td></tr></table>

# In house: ACE CK Reagent

One hundred nineteen serum samples were assayed in parallel by both the candidate and predicate methods. The results were analyzed by using Deming regression. The range tested was 16 to $1 3 4 5 \mathrm { U / L }$ . Altered samples were included in the study (no more than $1 0 \%$ ).

The comparison by Deming regression resulted in a slope of 1.016 $( 9 5 \% C \mathrm { I } = 1 . 0 0 9$ to 1.023), an intercept of - 0.1 $9 5 \% C \mathrm { I } = - 2 . 6$ to 2.4), correlation coefficient $( \mathrm { R } ^ { 2 } ) = 0 . 9 9 9 4$ , and a standard error of 10.6.

# Point of Care Laboratory: ACE CK Reagent

Serum samples were assayed in parallel by both the candidate and predicate methods at three POC sites. The results were analyzed by using Deming regression. (Some altered samples were used among all three sites.)

<table><tr><td>POL</td><td>n</td><td>Range</td><td>Regression Equation</td><td>Correlation Coefficient</td><td>Standard Error</td><td>Confidence Interval Slope</td><td>Confidence Interval Intercept</td></tr><tr><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">62</td><td colspan="1" rowspan="1">28-1325</td><td colspan="1" rowspan="1">y = 1.048x -2.9</td><td colspan="1" rowspan="1">0.9997</td><td colspan="1" rowspan="1">10.9</td><td colspan="1" rowspan="1">1.041 to1.055</td><td colspan="1" rowspan="1">-6.4 to 0.6</td></tr><tr><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">46</td><td colspan="1" rowspan="1">21-1165</td><td colspan="1" rowspan="1">y = 1.044x -3.0</td><td colspan="1" rowspan="1">0.9997</td><td colspan="1" rowspan="1">5.9</td><td colspan="1" rowspan="1">1.036 to1.052</td><td colspan="1" rowspan="1">-5.2 to -0.8</td></tr><tr><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">48</td><td colspan="1" rowspan="1">15-1281</td><td colspan="1" rowspan="1">y = 0.996x+0.9</td><td colspan="1" rowspan="1">0.9997</td><td colspan="1" rowspan="1">7.2</td><td colspan="1" rowspan="1">0.988 to1.003</td><td colspan="1" rowspan="1">-1.8 to 3.5</td></tr></table>

3. Clinical studies: Not applicable

4. Clinical cut-off: Not applicable

5. Expected values/Reference range:

BUN: 6-20 mg/dL

Creatinine: Male: $0 . 9 { - } 1 . 3 ~ \mathrm { m g / d L }$ Female: 0.6-1.1 mg/dL

Uric acid: Male: $3 . 5 \mathrm { ~ - ~ } 7 . 2 \mathrm { ~ m g / d L }$ Female: $2 . 6 - 6 . 0 \ \mathrm { m g / d L }$

CK: Male: 38 - 174 U/L Female: 26 - 140 U/L

Reference: Tietz N.W..Clinical Guide to Laboratory Tests $3 ^ { \mathrm { r d } }$ Ed (W.B. Saunders, 1995)

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.